Axalbion Therapeutics Limited

📍 Manchester, United Kingdom🗓 Founded 2021👥 6 employees💰 Last funded Apr 2024
Pharmaceutical Manufacturing🌐 axalbion.com
Website LinkedIn
Axalbion is a clinical-stage pharmaceutical company developing TRPM8 agonists for the treatment of chronic cough and dry eyes, two chronic, common and debilitating disorders, with unmet needs and multi-billion-dollar markets. Its molecules have a rapid onset of action and offer innovative topical treatment opportunities by normalizing abnormal cough and lacrimation reflexes. Axalbion’s s strategy is to develop its lead compound AX-8 up-to Phase 2b to show clinical proof of concept across a representative patient population. It has already been tested in a Phase 2a trial with patients suffering from refractory chronic cough. Axalbion benefits from having proof of concept studies (clinical and non-clinical), strong safety and toxicology data, and the support of world’s leading experts and strategic partners. WE WELCOME PRIVATE INVESTORS AND VCs TO CONTACT US DIRECTLY FOR FURTHER DETAILS. contact@axalbion.com
1
Total investors
0
Early stage
1
Mid stage
0
Late stage
2021
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Axalbion Therapeutics Limited?
Axalbion Therapeutics Limited has 1 investors on record on gritt.io, 1 mid-stage.
When did Axalbion Therapeutics Limited last raise funding?
The most recent investment in Axalbion Therapeutics Limited recorded on gritt.io was in April 2024.
When was Axalbion Therapeutics Limited founded?
Axalbion Therapeutics Limited was founded in 2021.
What industry is Axalbion Therapeutics Limited in?
Axalbion Therapeutics Limited operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is Axalbion Therapeutics Limited based?
Axalbion Therapeutics Limited is headquartered in Manchester, United Kingdom.